Biospherics.net has completed a Phase 2 and a Phase 3 clinical trial of BSN175, which has an FDA orphan drug designation. Biospherics.net is developing BSN175 (and BSN272) as treatments for Prader Willi Syndrome. Biospherics.net's BSN389 is also an FDA-designated orphan drug for the treatment of Ebola virus infections. Recently, studies began investigating the use of BSN389 as a treatment for COVID-19 infections as well. The company also has BSN476 for Chikungunya, and BSN908 in testing as a drug treatment for abdominal aortic aneurysms (AAAs). Biospherics.net is also working on a drug:device combination therapy for ADHD in FXS.
Biospherics.net is dedicated to keeping shareholders, the news media, and the public informed about business events, corporate capabilities, and other significant items affecting the Company, its markets, and its shareholders. Please check back often to access the latest news on Biospherics.net.
Media Inquiries should be addressed to:
Investor Relations
(301) 859-3230
info @ biospherics.info